$14.55
2.03% today
NYSE, Oct 03, 03:52 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$14.26
-0.36 2.46% 1M
+1.74 13.90% 6M
-6.39 30.94% YTD
+0.32 2.30% 1Y
-13.94 49.43% 3Y
-32.74 69.66% 5Y
-32.74 69.66% 10Y
-32.74 69.66% 20Y
NYSE, Closing price Thu, Oct 02 2025
-0.45 3.06%

Key metrics

Basic
Market capitalization
$834.0m
Enterprise Value
$2.1b
Net debt
$1.3b
Cash
$230.6m
Shares outstanding
58.5m
Valuation (TTM | estimate)
P/E
10.0 | 4.8
P/S
0.8 | 0.8
EV/Sales
1.9 | 1.9
EV/FCF
15.9
P/B
negative
Dividends
DPS
$0.60
Yield 1Y | 5Y
4.2% | 1.9%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
44.8% | 20.9%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$1.1b | $1.1b
EBITDA
$353.1m | $413.5m
EBIT
$316.0m | $341.4m
Net Income
$83.6m | $172.4m
Free Cash Flow
$132.3m
Growth (TTM | estimate)
Revenue
-1.5% | -1.7%
EBITDA
53.0% | 28.7%
EBIT
38.5% | 19.8%
Net Income
19.9% | 120.1%
Free Cash Flow
865.7%
Margin (TTM | estimate)
Gross
64.0%
EBITDA
32.0% | 37.5%
EBIT
28.7%
Net
7.6% | 15.6%
Free Cash Flow
12.0%
Financial Health
Equity Ratio
-57.4%
Return on Equity
-10.6%
ROCE
35.8%
ROIC
31.4%
Debt/Equity
-2.2
More
EPS
$1.4
FCF per Share
$2.3
Short interest
6.3%
Employees
2k
Rev per Employee
$530.0k
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Embecta forecast:

1x Buy
11%
4x Hold
44%
4x Sell
44%

Analyst Opinions

9 Analysts have issued a Embecta forecast:

Buy
11%
Hold
44%
Sell
44%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,103 1,103
1% 1%
100%
- Direct Costs 398 398
6% 6%
36%
705 705
5% 5%
64%
- Selling and Administrative Expenses 342 342
6% 6%
31%
- Research and Development Expense 37 37
55% 55%
3%
353 353
53% 53%
32%
- Depreciation and Amortization 37 37
1,327% 1,327%
3%
EBIT (Operating Income) EBIT 316 316
38% 38%
29%
Net Profit 84 84
20% 20%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Positive
Seeking Alpha
about one month ago
Embecta's restructuring and discontinuation of the patch pump system have significantly improved profitability, enabling substantial cost savings and debt reduction. The company is refocusing on core strengths, expanding into drug delivery and chronic care, and leveraging new pharma partnerships for broader growth. Financial guidance shows strong adjusted EPS and EBITDA margin growth, with cost...
Positive
Seeking Alpha
about one month ago
EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on strengthening the core insulin delivery business and expanding into adjacent markets while aggressively deleveraging. Short-term revenue headwinds persist due to a shrinking core market, but EMBC's reput...
Neutral
GlobeNewsWire
about one month ago
PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,100
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today